In 2021, 3 out of 4 patients who tried to fill a launch brand were unsuccessful due to payer controls. As life science companies continue to launch innovative specialty-lite therapies, adopting a distribution strategy that ensures patients can access the brand as prescribed – efficiently and affordably – can mean the difference between a successful launch and failing to reach their expected value. As the primary channel for most brands, pharmacy networks play a pivotal role in the distribution, fulfillment, and reimbursement of medications, which means the brand's short- and long-term commercial success ultimately hinges on pharmacy performance
The explosion of virtual healthcare during the COVID-19 pandemic fueled the rise of digital direct-to-consumer (DTC) channels in the life sciences industry. The realization that it’s possible for patients to have a compliant, clinical conversation to receive a prescription via a telemedicine platform linked to a brand’s website can be a game-changer. A well-executed DTC model provides a more responsive option for patients to meet them where they are in 2023 - online and on their phone
Talicia® is indicated for the treatment of Helicobacter pylori infection in adults Patients can now access RedHill’s Talicia® via the PhilRx Platform SAN FRANCISCO, Calif. – July 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform. The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting the moment the physician writes a prescription
Medication nonadherence is a long-standing problem linked to poor health outcomes, increased hospitalizations, and significantly higher healthcare costs. According to the CDC, out of the 3.8 billion prescriptions written in the U.S., one out of five are never filled. Even with good insurance and drug coverage, medication adherence rates for chronic conditions fall between 50-60%– a far cry from the 80% adherence rates medical experts say are necessary for optimal therapeutic efficacy
Low enrollment in manufacturer-sponsored patient services programs is rampant, so much so that many industry stakeholders have come to accept this as inevitable. This disappointing trend nearly always holds true if brands employ traditional “call center-based” hubs or specialty pharmacies that lack consumer-friendliness, creating unnecessary friction for patients and HCPs. These “clunky” programs typically result in enrollment rates between 20-30%
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.
Our expert team can build a tailored access program that drives your brand goals.
Our Solution
About Us